Lv43
638 积分 2025-05-27 加入
SHR2554, an EZH2 inhibitor, in relapsed or refractory mature lymphoid neoplasms: a first-in-human, dose-escalation, dose-expansion, and clinical expansion phase 1 trial
20小时前
已完结
Benzothiophene-based, orally active PIK3CA H1047R mutant-selective inhibitors for the treatment of HR+/HER2- breast cancer
2天前
已完结
Preclinical characterization of TOS-358, a potent and selective covalent inhibitor of wild-type and mutant PI3Kα with superior anticancer activity
17天前
已完结
Core-shell lipoplexes inducing active macropinocytosis promote intranasal delivery of c-Myc siRNA for treatment of glioblastoma
22天前
已完结
Small-molecule inhibitors of the Myc oncoprotein
1个月前
已完结
Functional interactions among members of the MAX and MLX transcriptional network during oncogenesis
1个月前
已完结
MYC, MYCL, and MYCN as therapeutic targets in lung cancer
1个月前
已完结
Myc proteins in cell biology and pathology
1个月前
已完结
MYC in cancer: from undruggable target to clinical trials
1个月前
已完结
177Lu-PSMA-617 versus a change of androgen receptor pathway inhibitor therapy for taxane-naive patients with progressive metastatic castration-resistant prostate cancer (PSMAfore): a phase 3, randomised, controlled trial
1个月前
已完结
皖公网安备34019202002308
